SSTR5 antagonist 1 manufacturers
|
| | SSTR5 antagonist 1 Basic information |
| Product Name: | SSTR5 antagonist 1 | | Synonyms: | SSTR5 antagonist 1;4-Piperidinecarboxylic acid, 1-[2-[(2,6-diethoxy-4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-5-oxa-2,6-diazaspiro[3.4]oct-6-en-7-yl]-;SSTR5 antagonist 1,SSTR-5 antagonist 1 | | CAS: | 1628741-91-2 | | MF: | C28H34FN3O5 | | MW: | 511.59 | | EINECS: | | | Product Categories: | | | Mol File: | 1628741-91-2.mol |  |
| | SSTR5 antagonist 1 Chemical Properties |
| Boiling point | 614.2±65.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 90 mg/mL (175.92 mM; Need ultrasonic) | | pka | 4.48±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | SSTR5 antagonist 1 Usage And Synthesis |
| Uses | SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively[1]. | | in vivo | SSTR5 antagonist 1 (compound 25a) (1 mg/kg; p.o.; single dose) is orally available with acceptable plasma exposure in mice in pharmacokinetic screening and exhibits excellent solubility (260 μg/mL, pH=6.8)[1].
SSTR5 antagonist 1 (100 mg/kg; p.o.; single dose; measured at 0-120 min) augments insulin secretion in a glucose-dependent manner and lowers blood glucose concentration in high-fat diet fed C57BL/6J mice[1].
SSTR5 antagonist 1 (1, 3, 10, and 30 mg/kg; p.o.; single dose) shows dose-dependent effect on glucose excursion measured during the oral glucose tolerance test in HFD fed C57BL/6J mice[1].
Pharmacokinetic profiles in male ICR mouse (8-week-old)[1] | Route | Dose (mg/kg) | CLtotal (mL/h/kg) | Vss (mL/kg) | MRT (h) | | | iv | 0.1 | 1761 | 3052 | 1.7 | / | | Route | Dose (mg/kg) | Cmax (ng/mL) | Tmax (h) | AUC0-8 h (ng·h/mL) | F (%) | | po | 1 | 74.8 | 2.0 | 332 | 58 |
| Animal Model: | High-fat diet fed C57BL/6J mice[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; single dose; monitored over 2 h | | Result: | Showed the maximum efficacy superior to that of 10 mg/kg Glibenclamide (HY-15206) and comparable to that of 30 mg/kg Alogliptin (HY-A0023A).
Augmented insulin secretion in a glucose-dependent manner and displayed a blood glucose-lowering effect, indicating its anti-diabetic efficacy in vivo. |
| | References | [1] Hirose H, et al. Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2017 Aug 1;25(15):4175-4193. DOI:10.1016/j.bmc.2017.06.007 |
| | SSTR5 antagonist 1 Preparation Products And Raw materials |
|